@article{610ace10e31f4665b4b97cfb8e70bbd8,
title = "Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia",
keywords = "anthracycline, favorable risk acute myeloid leukemia, gemtuzumab ozogamicin, overall survival, relapse-free survival",
author = "Mort, \{Joseph F.\} and David Brighton and Samantha DiBenedetto and Leah Wells and Clark, \{Stephen M.\} and Justin Reid and Imari Patel and Clayton Jackson and Bradley Yelvington and Ryan Miller and Matthew Perciavalle and Katherine Walsh and Heather Wolfe and Locke, \{Susan C.\} and Zeidner, \{Joshua F.\} and Duong, \{Vu H.\} and Reed, \{Daniel R.\} and Bhagirathbhai Dholaria and LeBlanc, \{Thomas W.\} and Michael Keng and Bethany Horton and \{El Chaer\}, Firas",
note = "Publisher Copyright: {\textcopyright} 2024 John Wiley \& Sons A/S. Published by John Wiley \& Sons Ltd.",
year = "2025",
month = mar,
doi = "10.1111/ejh.14354",
language = "English",
volume = "114",
pages = "481--494",
journal = "European Journal of Haematology",
issn = "0902-4441",
number = "3",
}